Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland

11. Literatur 211
119. Die Gesundheitsberichtserstattung des Bundes. Gesundheitsbericht für Deutschland
1998. 2002.
120. DISCERN-Online. DISCERN-Online – Qualitätskriterien für Patienteninformationen.
2002.
121. Dodd G, Fry K, Delany W. Pre-operative localization of occult carcinoma of the breast.
In: Nealon TF. Management of the patient with cancer. Philadelphia: Saunders,
1965:88–113.
122. Dowlatshahi K, Yaremko ML, Kluskens LF, Jokich PM. Nonpalpable breast lesions:
Findings of stereotaxic needle-core biopsy and fine-needle aspiration cytology.
Radiology 1991;185:639–40.
123. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast
disease. N Engl J Med 1985;312:146–51.
124. Dupont WD, Parl FF, Hartmann WH, Brinton LA,Winfield AC, et al. Breast cancer risk
associated with proliferative breast cancer disease and atypical hyperplasia. Cancer
1993;71:1258–65.
125. EC working group on breast screening pathology. Quality assurance guidelines for
pathology in mammography screening – non-operative diagnosis. chap.6, in European
guidelines for quality assurance in mammography screening, 3rd ed., edited by Perry N,
Broders M, de Wolf C, Törnberg S, Schouten J, Luxembourg, Office for Official
Publications of the European Communities 2001;159–72.
126. EC working group on breast screening pathology. Quality assurance guidelines for
pathology in mammography screening – open biopsy and resection specimens. chap.7,
in European guidelines for quality assurance in mammography screening, 3rd ed.,
edited by Perry N, Broders M, de Wolf C, Törnberg S, Schouten J, Luxembourg, Office
for Official Publications of the European Communities 2001;173–211.
127. Eccles M, Clapp Z, Grimshaw J, Adams P, Higgins B, Purves I, et al. North of England
evidence-based guidelines development project: methods of guideline development.
BMJ 1996;312:760–6.
128. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. 1.The value of histological
grade in breast cancer: experience from a large study with long-term followup.
Histopathology 1991;19:403–10.
129. Elston CW, Ellis IO. The Breast. 3rd ed.London, Churchill Livingstone 1998.
130. Engel J, Ludwig S, Schubert-Fritschle G,Tretter W, Hölzel D. Cancer prevention and the
contribution of cancer registries. J Cancer Res Clin Oncol 2001;127:331–9.
131. Engel J, Baumert J, Dirschedl P, Sauer H, Hölzel D. Wirksamkeit der Selbstuntersuchung,
Palpation und Mammographie zur Früherkennung des Mammakarzinoms:
Erste Ergebnisse der Feldstudie München. Geburtsh Frauenheilk 2000;60:155–64.
132. Engel J, Baumert J, Hölzel D. Brustkrebsfrüherkennung in Deutschland – Zeit zum
Handeln. Radiologe 2000;40:177–83.
133. Engel J, Heywang-Köbrunner SH, Schreer I, Hölzel D. Mammographie-Screening in
Deutschland – kritische Anmerkungen zu dem geplanten Erprobungsmodell.
Onkologe 1999;5:1111–5.
134. Engel J, Nagel G, Breuer E, Meisner C, Albert US, et al. Primary breast cancer therapy
in six regions of Germany. Eur J Cancer 2001;38:578–85.
135. Engel J, von Klot-Heydenfeldt S. Früherkennung des Mammakarzinoms in Deutschland
wirkungslos? Der Onkologe 1999;5:933–4.
136. Entwistle VA, Sheldon TA, Sowden AJ, Warr IS. Supporting consumer involvement in
decision making: what constitutes quality in consumer health information? Int J Qual
Health Care 1996;8:425–37.
137. EORTC Breast Cancer Cooperative Group. Manual for clinical research and treatment
in breast cancer. 4 ed. Almere, Netherlands, Excerpta Medica 2000.